Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile
AJ Scheen - Expert Opinion on Drug Safety, 2024 - Taylor & Francis
Introduction Patients with type 2 diabetes (T2DM) are at high risk of atherosclerotic
cardiovascular disease (ASCVD) and cardiovascular death. Cardiovascular protection is a …
cardiovascular disease (ASCVD) and cardiovascular death. Cardiovascular protection is a …
Effect of combination pioglitazone with sodium‐glucose cotransporter‐2 inhibitors or glucagon‐like peptide‐1 receptor agonists on outcomes in type 2 diabetes: A …
Aims To evaluate the efficacy and cardiovascular outcomes of combination pioglitazone with
either a glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) or a sodium‐glucose …
either a glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) or a sodium‐glucose …
Frail hypertensive older adults with prediabetes and chronic kidney disease: insights on organ damage and cognitive performance-preliminary results from the …
Background Hypertension and chronic kidney disease (CKD) pose significant public health
challenges, sharing intertwined pathophysiological mechanisms. Prediabetes is recognized …
challenges, sharing intertwined pathophysiological mechanisms. Prediabetes is recognized …
A review of the latest real‐world evidence studies in diabetic kidney disease: What have we learned about clinical practice and the clinical effectiveness of …
Diabetic nephropathy, also known as diabetic kidney disease (DKD), remains a challenge in
clinical practice as this is the major cause of kidney failure worldwide. Clinical trials do not …
clinical practice as this is the major cause of kidney failure worldwide. Clinical trials do not …
Comparison of GLP-1 receptor agonists and other Glucose-Lowering agents on cardiovascular outcomes in individuals with type 2 diabetes and Obesity: A Spanish …
A Palanca, FJ Ampudia-Blasco, JM Calderón… - Diabetes Research and …, 2024 - Elsevier
Aims Assess the impact of glucagon-like peptide receptor agonists (GLP-1RA) compared to
other glucose-lowering agents on cardiovascular outcomes in individuals with type 2 …
other glucose-lowering agents on cardiovascular outcomes in individuals with type 2 …
Glucagon‐like peptide‐1 receptor agonists and kidney outcomes
RJ MacIsaac, P Trevella, EI Ekinci - Journal of Diabetes, 2024 - Wiley Online Library
Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have gained increasing attention
for their potential benefits in people with type 2 diabetes mellitus (T2DM) with chronic kidney …
for their potential benefits in people with type 2 diabetes mellitus (T2DM) with chronic kidney …
Emerging evidence for glucagon-like peptide-1 agonists in slowing chronic kidney disease progression
MW Holliday Jr, L Frost… - Current Opinion in …, 2024 - journals.lww.com
GLP-1 receptor agonism is a promising therapy for slowing the progression of diabetic
chronic kidney disease. Recent studies support kidney benefits GLP-1 receptor agonists …
chronic kidney disease. Recent studies support kidney benefits GLP-1 receptor agonists …